Polaryx Therapeutics (PLYX) vs PolyPid (PYPD)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
PolyPid is the larger company by market cap ($103.0 million vs $99.7 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | PLYX | PYPD |
|---|---|---|
| Share price | $2.00 | $5.07 |
| Market cap | $99.69M | $102.98M |
| 1-day change | 0.00% | +3.47% |
| YTD return | — | +12.90% |
| 1-year return | — | +42.86% |
| 5-year return | — | -97.83% |
| EPS (TTM) | $-0.14 | $-1.44 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $48.91 | $5.73 |
| 52-week low | $1.85 | $3.06 |
| Distance from 52-week high | -95.91% | -11.52% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +275.00% | +131.76% |
| Average volume | 76.41K | 176.73K |
| Shares outstanding | 49.85M | 20.31M |
| Employees | 2 | 69 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Polaryx Therapeutics
PLYX stock →Polaryx Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of disease-modifying therapies for rare and pediatric lysosomal storage disorders in the United States. Its pipeline includes PLX-100, a preclinical stage orally administrable combination therapy; PLX-200, a repurposed oral small molecule for the treatment of LSDs; PLX-300, a preclinical stage orally administrable combination therapy; and PLX-400, a preclinical stage novel gene therapy candidate.
Health Care · Biotechnology: Pharmaceutical Preparations · 2 employees
About PolyPid
PYPD stock →PolyPid Ltd., a biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions.
Health Care · Medical/Dental Instruments · 69 employees
PLYX vs PYPD FAQ
Which is bigger, Polaryx Therapeutics or PolyPid?
PolyPid (PYPD) is larger, with a market capitalization of $102.98M compared with $99.69M for Polaryx Therapeutics (PLYX).
Are Polaryx Therapeutics and PolyPid in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for Polaryx Therapeutics and Medical/Dental Instruments for PolyPid.